Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 341 entries
Sorted by: Best Match Show Resources per page
Retraction. Angiotensin II receptor blocker provides pancreatic beta-cell protection independent of blood pressure lowering in diabetic db/db mice.

Acta pharmacologica Sinica

Shao JQ, Iwashita N, Du H, Wang YT, Wang YY, Zhao M, Wang J, Watada H, Kawamori R.
PMID: 17974074
Acta Pharmacol Sin. 2007 Oct;28(10):1705.

No abstract available.

Cite
Shao JQ, Iwashita N, Du H, et al. Retraction. Angiotensin II receptor blocker provides pancreatic beta-cell protection independent of blood pressure lowering in diabetic db/db mice. Acta Pharmacol Sin. 2007;28(10):1705
Shao, J. Q., Iwashita, N., Du, H., Wang, Y. T., Wang, Y. Y., Zhao, M., Wang, J., Watada, H., & Kawamori, R. (2007). Retraction. Angiotensin II receptor blocker provides pancreatic beta-cell protection independent of blood pressure lowering in diabetic db/db mice. Acta pharmacologica Sinica, 28(10), 1705.
Shao, J Q, et al. "Retraction. Angiotensin II receptor blocker provides pancreatic beta-cell protection independent of blood pressure lowering in diabetic db/db mice." Acta pharmacologica Sinica vol. 28,10 (2007): 1705.
Shao JQ, Iwashita N, Du H, Wang YT, Wang YY, Zhao M, Wang J, Watada H, Kawamori R. Retraction. Angiotensin II receptor blocker provides pancreatic beta-cell protection independent of blood pressure lowering in diabetic db/db mice. Acta Pharmacol Sin. 2007 Oct;28(10):1705. PMID: 17974074.
Copy Download .nbib Format: NLM
Ubiquitin-proteasome system, a new anti-tumor target.

Acta pharmacologica Sinica

Du W, Mei QB.
PMID: 23381108
Acta Pharmacol Sin. 2013 Feb;34(2):187-8. doi: 10.1038/aps.2012.192.

No abstract available.

Cite
Du W, Mei QB. Ubiquitin-proteasome system, a new anti-tumor target. Acta Pharmacol Sin. 2013;34(2):187-8doi: 10.1038/aps.2012.192.
Du, W., & Mei, Q. B. (2013). Ubiquitin-proteasome system, a new anti-tumor target. Acta pharmacologica Sinica, 34(2), 187-8. https://doi.org/10.1038/aps.2012.192
Du, Wei, and Mei, Qi-bing. "Ubiquitin-proteasome system, a new anti-tumor target." Acta pharmacologica Sinica vol. 34,2 (2013): 187-8. doi: https://doi.org/10.1038/aps.2012.192
Du W, Mei QB. Ubiquitin-proteasome system, a new anti-tumor target. Acta Pharmacol Sin. 2013 Feb;34(2):187-8. doi: 10.1038/aps.2012.192. PMID: 23381108; PMCID: PMC4011612.
Copy Download .nbib Format: NLM
Increased asynchronous GABA release causes more inhibition in human epileptic brain?.

Acta pharmacologica Sinica

Fang Q, Chen Z.
PMID: 22764074
Acta Pharmacol Sin. 2012 Jul;33(7):859-60. doi: 10.1038/aps.2012.92.

No abstract available.

Cite
Fang Q, Chen Z. Increased asynchronous GABA release causes more inhibition in human epileptic brain?. Acta Pharmacol Sin. 2012;33(7):859-60doi: 10.1038/aps.2012.92.
Fang, Q., & Chen, Z. (2012). Increased asynchronous GABA release causes more inhibition in human epileptic brain?. Acta pharmacologica Sinica, 33(7), 859-60. https://doi.org/10.1038/aps.2012.92
Fang, Qi, and Chen, Zhong. "Increased asynchronous GABA release causes more inhibition in human epileptic brain?." Acta pharmacologica Sinica vol. 33,7 (2012): 859-60. doi: https://doi.org/10.1038/aps.2012.92
Fang Q, Chen Z. Increased asynchronous GABA release causes more inhibition in human epileptic brain?. Acta Pharmacol Sin. 2012 Jul;33(7):859-60. doi: 10.1038/aps.2012.92. PMID: 22764074; PMCID: PMC4011148.
Copy Download .nbib Format: NLM
Wogonin protects glomerular podocytes by targeting Bcl-2-mediated autophagy and apoptosis in diabetic kidney disease.

Acta pharmacologica Sinica

Liu XQ, Jiang L, Li YY, Huang YB, Hu XR, Zhu W, Wang X, Wu YG, Meng XM, Qi XM.
PMID: 34253875
Acta Pharmacol Sin. 2022 Jan;43(1):96-110. doi: 10.1038/s41401-021-00721-5. Epub 2021 Jul 12.

Diabetic kidney disease (DKD) is one of the microvascular complications of diabetes mellitus and a major cause of end-stage renal disease with limited treatment options. Wogonin is a flavonoid derived from the root of Scutellaria baicalensis Georgi, which has...

Cite
Liu XQ, Jiang L, Li YY, et al. Wogonin protects glomerular podocytes by targeting Bcl-2-mediated autophagy and apoptosis in diabetic kidney disease. Acta Pharmacol Sin. 2021;43(1):96-110doi: 10.1038/s41401-021-00721-5.
Liu, X. Q., Jiang, L., Li, Y. Y., Huang, Y. B., Hu, X. R., Zhu, W., Wang, X., Wu, Y. G., Meng, X. M., & Qi, X. M. (2022). Wogonin protects glomerular podocytes by targeting Bcl-2-mediated autophagy and apoptosis in diabetic kidney disease. Acta pharmacologica Sinica, 43(1), 96-110. https://doi.org/10.1038/s41401-021-00721-5
Liu, Xue-Qi, et al. "Wogonin protects glomerular podocytes by targeting Bcl-2-mediated autophagy and apoptosis in diabetic kidney disease." Acta pharmacologica Sinica vol. 43,1 (2022): 96-110. doi: https://doi.org/10.1038/s41401-021-00721-5
Liu XQ, Jiang L, Li YY, Huang YB, Hu XR, Zhu W, Wang X, Wu YG, Meng XM, Qi XM. Wogonin protects glomerular podocytes by targeting Bcl-2-mediated autophagy and apoptosis in diabetic kidney disease. Acta Pharmacol Sin. 2022 Jan;43(1):96-110. doi: 10.1038/s41401-021-00721-5. Epub 2021 Jul 12. PMID: 34253875.
Copy Download .nbib Format: NLM
Establishment of an in vitro safety assessment model for lipid-lowering drugs using same-origin human pluripotent stem cell-derived cardiomyocytes and endothelial cells.

Acta pharmacologica Sinica

Ni X, Yang ZZ, Ye LQ, Han XL, Zhao DD, Ding FY, Ding N, Wu HC, Yu M, Xu GY, Zhao ZA, Lei W, Hu SJ.
PMID: 33686244
Acta Pharmacol Sin. 2022 Jan;43(1):240-250. doi: 10.1038/s41401-021-00621-8. Epub 2021 Mar 08.

Cardiovascular safety assessment is vital for drug development, yet human cardiovascular cell models are lacking. In vitro mass-generated human pluripotent stem cell (hPSC)-derived cardiovascular cells are a suitable cell model for preclinical cardiovascular safety evaluations. In this study, we...

Cite
Ni X, Yang ZZ, Ye LQ, et al. Establishment of an in vitro safety assessment model for lipid-lowering drugs using same-origin human pluripotent stem cell-derived cardiomyocytes and endothelial cells. Acta Pharmacol Sin. 2021;43(1):240-250doi: 10.1038/s41401-021-00621-8.
Ni, X., Yang, Z. Z., Ye, L. Q., Han, X. L., Zhao, D. D., Ding, F. Y., Ding, N., Wu, H. C., Yu, M., Xu, G. Y., Zhao, Z. A., Lei, W., & Hu, S. J. (2022). Establishment of an in vitro safety assessment model for lipid-lowering drugs using same-origin human pluripotent stem cell-derived cardiomyocytes and endothelial cells. Acta pharmacologica Sinica, 43(1), 240-250. https://doi.org/10.1038/s41401-021-00621-8
Ni, Xuan, et al. "Establishment of an in vitro safety assessment model for lipid-lowering drugs using same-origin human pluripotent stem cell-derived cardiomyocytes and endothelial cells." Acta pharmacologica Sinica vol. 43,1 (2022): 240-250. doi: https://doi.org/10.1038/s41401-021-00621-8
Ni X, Yang ZZ, Ye LQ, Han XL, Zhao DD, Ding FY, Ding N, Wu HC, Yu M, Xu GY, Zhao ZA, Lei W, Hu SJ. Establishment of an in vitro safety assessment model for lipid-lowering drugs using same-origin human pluripotent stem cell-derived cardiomyocytes and endothelial cells. Acta Pharmacol Sin. 2022 Jan;43(1):240-250. doi: 10.1038/s41401-021-00621-8. Epub 2021 Mar 08. PMID: 33686244.
Copy Download .nbib Format: NLM
Diterbutyl phthalate attenuates osteoarthritis in ACLT mice via suppressing ERK/c-fos/NFATc1 pathway, and subsequently inhibiting subchondral osteoclast fusion.

Acta pharmacologica Sinica

Fang C, Guo JW, Wang YJ, Li XQ, Zhang H, Cui J, Hu Y, Jing YY, Chen X, Su JC.
PMID: 34381182
Acta Pharmacol Sin. 2021 Aug 11; doi: 10.1038/s41401-021-00747-9. Epub 2021 Aug 11.

Osteoarthritis (OA) is the most common arthritis with a rapidly increasing prevalence. Disease progression is irreversible, and there is no curative therapy available. During OA onset, abnormal mechanical loading leads to excessive osteoclastogenesis and bone resorption in subchondral bone,...

Cite
Fang C, Guo JW, Wang YJ, et al. Diterbutyl phthalate attenuates osteoarthritis in ACLT mice via suppressing ERK/c-fos/NFATc1 pathway, and subsequently inhibiting subchondral osteoclast fusion. Acta Pharmacol Sin. 2021;doi: 10.1038/s41401-021-00747-9.
Fang, C., Guo, J. W., Wang, Y. J., Li, X. Q., Zhang, H., Cui, J., Hu, Y., Jing, Y. Y., Chen, X., & Su, J. C. (2021). Diterbutyl phthalate attenuates osteoarthritis in ACLT mice via suppressing ERK/c-fos/NFATc1 pathway, and subsequently inhibiting subchondral osteoclast fusion. Acta pharmacologica Sinica, . https://doi.org/10.1038/s41401-021-00747-9
Fang, Chao, et al. "Diterbutyl phthalate attenuates osteoarthritis in ACLT mice via suppressing ERK/c-fos/NFATc1 pathway, and subsequently inhibiting subchondral osteoclast fusion." Acta pharmacologica Sinica vol. (2021). doi: https://doi.org/10.1038/s41401-021-00747-9
Fang C, Guo JW, Wang YJ, Li XQ, Zhang H, Cui J, Hu Y, Jing YY, Chen X, Su JC. Diterbutyl phthalate attenuates osteoarthritis in ACLT mice via suppressing ERK/c-fos/NFATc1 pathway, and subsequently inhibiting subchondral osteoclast fusion. Acta Pharmacol Sin. 2021 Aug 11; doi: 10.1038/s41401-021-00747-9. Epub 2021 Aug 11. PMID: 34381182.
Copy Download .nbib Format: NLM
CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia.

Acta pharmacologica Sinica

Zhao ZA, Jiang Y, Chen YY, Wu T, Lan QS, Li YM, Li L, Yang Y, Lin CT, Cao Y, Zhou PZ, Guo JY, Tian YX, Pang JX.
PMID: 33767379
Acta Pharmacol Sin. 2021 Mar 25; doi: 10.1038/s41401-021-00640-5. Epub 2021 Mar 25.

Urate transporter 1 (URAT1) and glucose transporter 9 (GLUT9) are important targets for the development of uric acid-lowering drugs. We previously showed that the flexible linkers of URAT1 inhibitors could enhance their potency. In this study we designed and...

Cite
Zhao ZA, Jiang Y, Chen YY, et al. CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia. Acta Pharmacol Sin. 2021;doi: 10.1038/s41401-021-00640-5.
Zhao, Z. A., Jiang, Y., Chen, Y. Y., Wu, T., Lan, Q. S., Li, Y. M., Li, L., Yang, Y., Lin, C. T., Cao, Y., Zhou, P. Z., Guo, J. Y., Tian, Y. X., & Pang, J. X. (2021). CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia. Acta pharmacologica Sinica, . https://doi.org/10.1038/s41401-021-00640-5
Zhao, Ze-An, et al. "CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia." Acta pharmacologica Sinica vol. (2021). doi: https://doi.org/10.1038/s41401-021-00640-5
Zhao ZA, Jiang Y, Chen YY, Wu T, Lan QS, Li YM, Li L, Yang Y, Lin CT, Cao Y, Zhou PZ, Guo JY, Tian YX, Pang JX. CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia. Acta Pharmacol Sin. 2021 Mar 25; doi: 10.1038/s41401-021-00640-5. Epub 2021 Mar 25. PMID: 33767379.
Copy Download .nbib Format: NLM
Cystine supplementation rebalances the redox homeostasis of microenvironment in non-small cell lung cancer cells and reverses their resistance to docetaxel.

Acta pharmacologica Sinica

Li SJ, Cao B, Lu ZY, Sun RB, Guo SH, Xie Y, Aa JY, Wang GJ.
PMID: 33658706
Acta Pharmacol Sin. 2021 Dec;42(12):2132-2143. doi: 10.1038/s41401-020-00610-3. Epub 2021 Mar 03.

Continuous docetaxel (DTX) treatment of non-small cell lung cancer induces development of drug resistance, but the mechanism is poorly understood. In this study we performed metabolomics analysis to characterize the metabolic patterns of sensitive and resistant A549 non-small cell...

Cite
Li SJ, Cao B, Lu ZY, et al. Cystine supplementation rebalances the redox homeostasis of microenvironment in non-small cell lung cancer cells and reverses their resistance to docetaxel. Acta Pharmacol Sin. 2021;42(12):2132-2143doi: 10.1038/s41401-020-00610-3.
Li, S. J., Cao, B., Lu, Z. Y., Sun, R. B., Guo, S. H., Xie, Y., Aa, J. Y., & Wang, G. J. (2021). Cystine supplementation rebalances the redox homeostasis of microenvironment in non-small cell lung cancer cells and reverses their resistance to docetaxel. Acta pharmacologica Sinica, 42(12), 2132-2143. https://doi.org/10.1038/s41401-020-00610-3
Li, Si-Jia, et al. "Cystine supplementation rebalances the redox homeostasis of microenvironment in non-small cell lung cancer cells and reverses their resistance to docetaxel." Acta pharmacologica Sinica vol. 42,12 (2021): 2132-2143. doi: https://doi.org/10.1038/s41401-020-00610-3
Li SJ, Cao B, Lu ZY, Sun RB, Guo SH, Xie Y, Aa JY, Wang GJ. Cystine supplementation rebalances the redox homeostasis of microenvironment in non-small cell lung cancer cells and reverses their resistance to docetaxel. Acta Pharmacol Sin. 2021 Dec;42(12):2132-2143. doi: 10.1038/s41401-020-00610-3. Epub 2021 Mar 03. PMID: 33658706; PMCID: PMC8632922.
Copy Download .nbib Format: NLM
Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity.

Acta pharmacologica Sinica

Cheng CJ, Liu KX, Zhang M, Shen FK, Ye LL, Wu WB, Hou XT, Hao EW, Hou YY, Bai G.
PMID: 34326484
Acta Pharmacol Sin. 2021 Jul 29; doi: 10.1038/s41401-021-00737-x. Epub 2021 Jul 29.

Heat shock protein 90 (HSP90) has been recognized as a crucial target in cancer cells. However, various toxic reactions targeting the ATP binding site of HSP90 may not be the best choice for HSP90 inhibitors. In this paper, an...

Cite
Cheng CJ, Liu KX, Zhang M, et al. Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity. Acta Pharmacol Sin. 2021;doi: 10.1038/s41401-021-00737-x.
Cheng, C. J., Liu, K. X., Zhang, M., Shen, F. K., Ye, L. L., Wu, W. B., Hou, X. T., Hao, E. W., Hou, Y. Y., & Bai, G. (2021). Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity. Acta pharmacologica Sinica, . https://doi.org/10.1038/s41401-021-00737-x
Cheng, Chuan-Jing, et al. "Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity." Acta pharmacologica Sinica vol. (2021). doi: https://doi.org/10.1038/s41401-021-00737-x
Cheng CJ, Liu KX, Zhang M, Shen FK, Ye LL, Wu WB, Hou XT, Hao EW, Hou YY, Bai G. Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity. Acta Pharmacol Sin. 2021 Jul 29; doi: 10.1038/s41401-021-00737-x. Epub 2021 Jul 29. PMID: 34326484.
Copy Download .nbib Format: NLM
Benzimidazoles induce concurrent apoptosis and pyroptosis of human glioblastoma cells via arresting cell cycle.

Acta pharmacologica Sinica

Ren LW, Li W, Zheng XJ, Liu JY, Yang YH, Li S, Zhang S, Fu WQ, Xiao B, Wang JH, Du GH.
PMID: 34433903
Acta Pharmacol Sin. 2021 Aug 25; doi: 10.1038/s41401-021-00752-y. Epub 2021 Aug 25.

Glioblastoma multiforme (GBM) is the most malignant and lethal primary brain tumor in adults accounting for about 50% of all gliomas. The only treatment available for GBM is the drug temozolomide, which unfortunately has frequent drug resistance issue. By...

Cite
Ren LW, Li W, Zheng XJ, et al. Benzimidazoles induce concurrent apoptosis and pyroptosis of human glioblastoma cells via arresting cell cycle. Acta Pharmacol Sin. 2021;doi: 10.1038/s41401-021-00752-y.
Ren, L. W., Li, W., Zheng, X. J., Liu, J. Y., Yang, Y. H., Li, S., Zhang, S., Fu, W. Q., Xiao, B., Wang, J. H., & Du, G. H. (2021). Benzimidazoles induce concurrent apoptosis and pyroptosis of human glioblastoma cells via arresting cell cycle. Acta pharmacologica Sinica, . https://doi.org/10.1038/s41401-021-00752-y
Ren, Li-Wen, et al. "Benzimidazoles induce concurrent apoptosis and pyroptosis of human glioblastoma cells via arresting cell cycle." Acta pharmacologica Sinica vol. (2021). doi: https://doi.org/10.1038/s41401-021-00752-y
Ren LW, Li W, Zheng XJ, Liu JY, Yang YH, Li S, Zhang S, Fu WQ, Xiao B, Wang JH, Du GH. Benzimidazoles induce concurrent apoptosis and pyroptosis of human glioblastoma cells via arresting cell cycle. Acta Pharmacol Sin. 2021 Aug 25; doi: 10.1038/s41401-021-00752-y. Epub 2021 Aug 25. PMID: 34433903.
Copy Download .nbib Format: NLM
P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib.

Acta pharmacologica Sinica

Zhou XR, Li X, Liao LP, Han J, Huang J, Li JC, Tao HR, Fan SJ, Chen ZF, Li Q, Chen SJ, Ding H, Yang YX, Zhou B, Jiang HL, Chen KX, Zhang YY, Huang CX, Luo C.
PMID: 33850273
Acta Pharmacol Sin. 2021 Apr 13; doi: 10.1038/s41401-021-00643-2. Epub 2021 Apr 13.

Mantle cell lymphoma (MCL) is a lymphoproliferative disorder lacking reliable therapies. PI3K pathway contributes to the pathogenesis of MCL, serving as a potential target. However, idelalisib, an FDA-approved drug targeting PI3Kδ, has shown intrinsic resistance in MCL treatment. Here...

Cite
Zhou XR, Li X, Liao LP, et al. P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib. Acta Pharmacol Sin. 2021;doi: 10.1038/s41401-021-00643-2.
Zhou, X. R., Li, X., Liao, L. P., Han, J., Huang, J., Li, J. C., Tao, H. R., Fan, S. J., Chen, Z. F., Li, Q., Chen, S. J., Ding, H., Yang, Y. X., Zhou, B., Jiang, H. L., Chen, K. X., Zhang, Y. Y., Huang, C. X., & Luo, C. (2021). P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib. Acta pharmacologica Sinica, . https://doi.org/10.1038/s41401-021-00643-2
Zhou, Xiao-Ru, et al. "P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib." Acta pharmacologica Sinica vol. (2021). doi: https://doi.org/10.1038/s41401-021-00643-2
Zhou XR, Li X, Liao LP, Han J, Huang J, Li JC, Tao HR, Fan SJ, Chen ZF, Li Q, Chen SJ, Ding H, Yang YX, Zhou B, Jiang HL, Chen KX, Zhang YY, Huang CX, Luo C. P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib. Acta Pharmacol Sin. 2021 Apr 13; doi: 10.1038/s41401-021-00643-2. Epub 2021 Apr 13. PMID: 33850273.
Copy Download .nbib Format: NLM
Inhibition of PDE4 by apremilast attenuates skin fibrosis through directly suppressing activation of M1 and T cells.

Acta pharmacologica Sinica

Lu QK, Fan C, Xiang CG, Wu B, Lu HM, Feng CL, Yang XQ, Li H, Tang W.
PMID: 33850274
Acta Pharmacol Sin. 2021 Apr 13; doi: 10.1038/s41401-021-00656-x. Epub 2021 Apr 13.

Systemic sclerosis (SSc) is a life-threatening chronic connective tissue disease with the characteristics of skin fibrosis, vascular injury, and inflammatory infiltrations. Though inhibition of phosphodiesterase 4 (PDE4) has been turned out to be an effective strategy in suppressing inflammation...

Cite
Lu QK, Fan C, Xiang CG, et al. Inhibition of PDE4 by apremilast attenuates skin fibrosis through directly suppressing activation of M1 and T cells. Acta Pharmacol Sin. 2021;doi: 10.1038/s41401-021-00656-x.
Lu, Q. K., Fan, C., Xiang, C. G., Wu, B., Lu, H. M., Feng, C. L., Yang, X. Q., Li, H., & Tang, W. (2021). Inhibition of PDE4 by apremilast attenuates skin fibrosis through directly suppressing activation of M1 and T cells. Acta pharmacologica Sinica, . https://doi.org/10.1038/s41401-021-00656-x
Lu, Qiu-Kai, et al. "Inhibition of PDE4 by apremilast attenuates skin fibrosis through directly suppressing activation of M1 and T cells." Acta pharmacologica Sinica vol. (2021). doi: https://doi.org/10.1038/s41401-021-00656-x
Lu QK, Fan C, Xiang CG, Wu B, Lu HM, Feng CL, Yang XQ, Li H, Tang W. Inhibition of PDE4 by apremilast attenuates skin fibrosis through directly suppressing activation of M1 and T cells. Acta Pharmacol Sin. 2021 Apr 13; doi: 10.1038/s41401-021-00656-x. Epub 2021 Apr 13. PMID: 33850274.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 341 entries